Toripalimab |
Katalog-Nr.GC64561
One-Click Copy Product Info
|
Toripalimab ist der erste inlÄndische Anti-Tumor-PD-1-AntikÖrper in China. Toripalimab ist ein selektiver, rekombinanter, humanisierter monoklonaler AntikÖrper gegen PD-1. Toripalimab ist in der Lage, an PD-1 zu binden und die Wechselwirkung mit seinen Liganden zu blockieren. Toripalimab hat primÄre Antitumorwirkungen bei Tumoren wie Melanomen, Lungenkrebs, Tumoren des Verdauungstrakts, hepatobiliÄren und pankreatischen Tumoren, neuroendokrinen Neoplasien, Nasopharynxkarzinom und Urothelkarzinom gezeigt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1924598-82-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Toripalimab is a recombinant humanized anti-PD-1 monoclonal antibody. Toripalimab binds to the PD-1 receptor on the surface of T cells, blocking PD-1 interaction with the ligands PD-L1 and PD-L2, thereby alleviating the PD-1 signaling pathway-mediated immune suppression[1-2]. Toripalimab can be used in research related to cancers such as melanoma, urothelial carcinoma, nasopharyngeal carcinoma, and esophageal squamous cell carcinoma[3-4].
In vitro, treatment of SEB-stimulated human peripheral blood mononuclear cells (PBMCs) with Toripalimab (3.3-10µg/mL) for 3 days, or treatment of anti-CD3/anti-CD28 stimulated human naïve CD8+ T cells for 3 days. Toripalimab significantly enhanced the secretion of Th1 cytokines (IFN-γ, IL-2, TNF) and myeloid-derived inflammatory cytokines (IL-1α, IL-1β), while also enhancing T cell activation. In ex vivo cultures of dissociated tumor cells from NSCLC patients, treatment with Toripalimab (10µg/mL) combined with anti-CD3/anti-CD28 stimulation for 6-24 hours significantly upregulated IFN-γ production and the expression of genes related to immune cell pathways[5]. Treatment of human PBMCs with Toripalimab (0.01-10µg/mL) for 6-10 days, Toripalimab stimulated human T cell proliferation in a dose-dependent manner and enhanced the secretion of IFN-γ and TNF-α[6].
In vivo, C57/hPD-1 knock-in mice bearing MC38 tumors were treated with Toripalimab (0.3-10mg/kg, intraperitoneal injection, twice weekly) for 3 weeks. Toripalimab significantly inhibited tumor growth in a dose-dependent manner[7]. hPD-1 knock-in mice subcutaneously inoculated with B16-vec or B16-IL33 melanoma cells were treated with Toripalimab (200µg/100µL, twice weekly, for 3 weeks). The combination of Toripalimab and IL-33 significantly suppressed tumor growth and prolonged the survival of tumor-bearing mice[8].
References:
[1] Zhang X, Zheng J, Niu Y, et al. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review. Front Immunol. 2022 Nov 30;13:1059331.
[2] Thuss-Patience P, Stein A. Immunotherapy in Squamous Cell Cancer of the Esophagus. Curr Oncol. 2022 Mar 30;29(4):2461-2471.
[3] Lian D, Yang Y, Gan Y, et al. Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):587-596.
[4] Zhang L, Hao B, Geng Z, et al. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
[5] Rajasekaran N, Wang X, Ravindranathan S, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024 Feb 24;73(3):60.
[6] Fu J, Wang F, Dong LH, et al. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin. 2017 May;38(5):710-718.
[7] Liu H, Guo L, Zhang J, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019 May/Jun;11(4):681-690.
[8] He H, Shi L, Meng D, et al. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner. Cancer Treat Res Commun. 2021;28:100379.
| Cell experiment [1]: | |
Cell lines | Human peripheral blood mononuclear cell (PBMC)-derived T cells |
Preparation Method | Human PBMCs were isolated and cultured for six days in the presence of IL-4 and GM-CSF to generate immature dendritic cells (imDCs). The imDCs were then incubated with TNF-α for three days to obtain mature dendritic cells (mDCs). T cells were isolated from the PBMCs of the same donors and labeled with CFSE. The mDCs, T cells, and Tetanus Toxoid (10ng/mL) were mixed. Different concentrations of Toripalimab (0.01 to 10μg/mL), Nivolumab (positive control), or hIgG4 (negative control) were added to the mixtures. |
Reaction Conditions | 0.01 to 10μg/mL; 10 days. |
Applications | Treatment with Toripalimab dose-dependently stimulated human T cell proliferation, as well as IFN-γ and TNF-α secretion. Toripalimab was more effective in promoting T cell proliferation and cytokine secretion at concentrations of 0.1-3μg/mL. |
| Animal experiment [2]: | |
Animal models | hPD-1 knock-in mice with a C57BL/6 background (C57/hPD-1 mice) |
Preparation Method | Mice were subcutaneously inoculated with 1 x 106 MC38 syngeneic tumor cells on day 0. On day 6, the inoculated mice were randomized into groups and treated via intraperitoneal injection with either control IgG, saline, or Toripalimab at 0.3-10mg/kg. |
Dosage form | 0.3-10mg/kg; i.p.; twice a week for 3 weeks. |
Applications | Toripalimab inhibited tumor growth in a dose-dependent manner, with substantial antitumor efficacy observed at doses of 1, 3, and 10mg/kg. |
References: | |
| Cas No. | 1924598-82-2 | SDF | |
| Formula | M.Wt | 147.3 kDa | |
| Löslichkeit | Storage | 4°C,do not freeze. | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.8 μL | 33.9 μL | 67.9 μL |
| 5 mM | 1.4 μL | 6.8 μL | 13.6 μL |
| 10 mM | 0.7 μL | 3.4 μL | 6.8 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)